Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 7.65
(0.79%)
SEK 7.65
(0.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -333.62 Million SEK | -29.95% |
| 2022 | -256.73 Million SEK | 12.64% |
| 2021 | -293.87 Million SEK | -18.27% |
| 2020 | -248.47 Million SEK | -32.6% |
| 2019 | -187.39 Million SEK | 16.6% |
| 2018 | -224.68 Million SEK | -835.46% |
| 2017 | -24.01 Million SEK | -463.03% |
| 2016 | -4.26 Million SEK | 83.05% |
| 2015 | -25.17 Million SEK | -11888.1% |
| 2014 | -210 Thousand SEK | 96.97% |
| 2013 | -6.92 Million SEK | -186608.01% |
| 2012 | -3709.00 SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -431 Million SEK | -29.19% |
| 2024 Q2 | -358.65 Million SEK | 16.79% |
| 2023 FY | -333.62 Million SEK | -29.95% |
| 2023 Q4 | -333.62 Million SEK | 4.97% |
| 2023 Q1 | -183.62 Million SEK | 28.48% |
| 2023 Q2 | -259.59 Million SEK | -41.37% |
| 2023 Q3 | -351.08 Million SEK | -35.25% |
| 2022 Q4 | -256.73 Million SEK | -51.36% |
| 2022 Q3 | -169.62 Million SEK | 28.24% |
| 2022 Q2 | -236.36 Million SEK | 21.31% |
| 2022 Q1 | -300.36 Million SEK | -2.21% |
| 2022 FY | -256.73 Million SEK | 12.64% |
| 2021 Q3 | -369.26 Million SEK | -0.74% |
| 2021 FY | -293.87 Million SEK | -18.27% |
| 2021 Q1 | -442.59 Million SEK | -78.02% |
| 2021 Q2 | -366.53 Million SEK | 17.18% |
| 2021 Q4 | -293.87 Million SEK | 20.41% |
| 2020 Q4 | -248.61 Million SEK | -16.3% |
| 2020 Q3 | -213.78 Million SEK | -58.53% |
| 2020 Q1 | -160.65 Million SEK | 14.27% |
| 2020 FY | -248.47 Million SEK | -32.6% |
| 2020 Q2 | -134.85 Million SEK | 16.06% |
| 2019 Q2 | -193.1 Million SEK | 10.59% |
| 2019 FY | -187.39 Million SEK | 16.6% |
| 2019 Q1 | -215.97 Million SEK | 3.88% |
| 2019 Q4 | -187.4 Million SEK | -8.83% |
| 2019 Q3 | -172.19 Million SEK | 10.83% |
| 2018 Q2 | -18.1 Million SEK | -31.71% |
| 2018 FY | -224.68 Million SEK | -835.46% |
| 2018 Q3 | -32.2 Million SEK | -77.93% |
| 2018 Q1 | -13.74 Million SEK | 42.78% |
| 2018 Q4 | -224.68 Million SEK | -597.59% |
| 2017 Q2 | -40.22 Million SEK | -48.84% |
| 2017 Q4 | -24.01 Million SEK | 26.62% |
| 2017 FY | -24.01 Million SEK | -463.03% |
| 2017 Q3 | -32.73 Million SEK | 18.62% |
| 2017 Q1 | -27.02 Million SEK | -533.5% |
| 2016 FY | -4.26 Million SEK | 83.05% |
| 2016 Q2 | -13.03 Million SEK | 29.23% |
| 2016 Q1 | -18.42 Million SEK | 26.82% |
| 2016 Q4 | -4.26 Million SEK | 52.16% |
| 2016 Q3 | -8.91 Million SEK | 31.6% |
| 2015 Q2 | -5 Million SEK | 0.0% |
| 2015 FY | -25.17 Million SEK | -11888.1% |
| 2015 Q4 | -25.17 Million SEK | 0.0% |
| 2014 Q3 | -4.04 Million SEK | 50.56% |
| 2014 Q4 | -210 Thousand SEK | 94.81% |
| 2014 Q1 | -8.18 Million SEK | -18.19% |
| 2014 Q2 | -8.18 Million SEK | 0.0% |
| 2014 FY | -210 Thousand SEK | 96.97% |
| 2013 Q4 | -6.92 Million SEK | -197.88% |
| 2013 Q3 | 7.07 Million SEK | 0.0% |
| 2013 FY | -6.92 Million SEK | -186608.01% |
| 2013 Q1 | 3709.00 SEK | 200.0% |
| 2012 Q4 | -3709.00 SEK | 0.0% |
| 2012 FY | -3709.00 SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -2.16 Million SEK | -15338.223% |
| BioArctic AB (publ) | -606.58 Million SEK | 45.001% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -1650.367% |
| CombiGene AB (publ) | -101.44 Million SEK | -228.884% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -306.427% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -1035.42% |
| OncoZenge AB (publ) | -12.62 Million SEK | -2542.116% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -566.96% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 6278.148% |
| Mendus AB (publ) | -96.29 Million SEK | -246.46% |
| LIDDS AB (publ) | -13.51 Million SEK | -2369.065% |
| Lipum AB (publ) | -8.46 Million SEK | -3841.17% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 726.834% |
| Simris Alg AB (publ) | 85.07 Million SEK | 492.148% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -637.82% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -2421.849% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 300.883% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -157.632% |
| Ziccum AB (publ) | -2.13 Million SEK | -15511.605% |
| AcouSort AB (publ) | -23.98 Million SEK | -1290.895% |
| Active Biotech AB (publ) | -33.2 Million SEK | -904.88% |
| Alzinova AB (publ) | -21.22 Million SEK | -1471.752% |
| Amniotics AB (publ) | -5.63 Million SEK | -5823.651% |
| Camurus AB (publ) | -1.16 Billion SEK | 71.371% |
| Cantargia AB (publ) | -139.74 Million SEK | -138.731% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -36045.179% |
| Genovis AB (publ.) | -43.94 Million SEK | -659.245% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -298.395% |
| Isofol Medical AB (publ) | -138.14 Million SEK | -141.495% |
| Intervacc AB (publ) | -88.16 Million SEK | -278.426% |
| Kancera AB (publ) | -45.69 Million SEK | -630.15% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -305.854% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -944.946% |
| NextCell Pharma AB | -46.79 Million SEK | -613.006% |
| Saniona AB (publ) | 40.44 Million SEK | 924.832% |
| Xintela AB (publ) | -7.8 Million SEK | -4172.25% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -568.122% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 1726.621% |
| Corline Biomedical AB | -17.01 Million SEK | -1861.086% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -298.386% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -747.138% |
| Aptahem AB (publ) | 2.9 Million SEK | 11569.957% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | -1.385% |
| Fluicell AB (publ) | -2.76 Million SEK | -11974.557% |
| Biovica International AB (publ) | -58.73 Million SEK | -467.99% |
| Abliva AB (publ) | -57.24 Million SEK | -482.844% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | -71.351% |
| 2cureX AB (publ) | -13.4 Million SEK | -2389.144% |
| I-Tech AB | -83.26 Million SEK | -300.687% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 347.662% |
| Cyxone AB (publ) | -16.67 Million SEK | -1901.32% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -496.965% |
| Biosergen AB | -1.88 Million SEK | -17617.472% |
| Nanologica AB (publ) | -9.38 Million SEK | -3453.686% |
| SynAct Pharma AB | -61.75 Million SEK | -440.205% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -1457.88% |
| BioInvent International AB (publ) | -236.3 Million SEK | -41.183% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -398.536% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -6339.397% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -1504.482% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -11125.437% |